MENU
+Compare
FMED
ETF ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$25.32
Change
-$0.07 (-0.28%)
Net Assets
53.83M

FMED stock forecast, quote, news & analysis

Category: @Health
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for FMED with price predictions
Jan 08, 2025

Momentum Indicator for FMED turns positive, indicating new upward trend

FMED saw its Momentum Indicator move above the 0 level on January 03, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator turned positive. In of the 29 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FMED's RSI Indicator exited the oversold zone, of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FMED just turned positive on January 06, 2025. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in of 15 cases over the following month. The odds of a continued upward trend are .

FMED moved above its 50-day moving average on January 08, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in of 93 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Regeneron Pharmaceuticals (NASDAQ:REGN), Edwards Lifesciences Corp (NYSE:EW), Humana (NYSE:HUM), Centene Corp (NYSE:CNC), Align Technology (NASDAQ:ALGN).

Industry description

The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.

Market Cap

The average market capitalization across the Fidelity Disruptive Medicine ETF ETF is 51.35B. The market cap for tickers in the group ranges from 91.77M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ALXO at 91.77M.

High and low price notable news

The average weekly price growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was 0%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was 3%. AGL experienced the highest price growth at 27%, while KROS experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Fidelity Disruptive Medicine ETF ETF was -5%. For the same stocks of the ETF, the average monthly volume growth was -3% and the average quarterly volume growth was 42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 69
Price Growth Rating: 55
SMR Rating: 78
Profit Risk Rating: 70
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
FMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
82 Devonshire StreetBoston
Phone
N/A
Web
www.institutional.fidelity.com